Jenkins defends approvable letters
A recent controversy about the FDA ducking its legal obligation to approve new drugs on time by issuing "approvable" letters is just silly, said FDA director of new drugs John Jenkins.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.